Cellectis S.A. (ZVA)
FSX
Closed
Aug 25, 2026
Day's Range
2.6952 wk Range
2.18Overview - ZVA - Cellectis S.A.
Key Statistics
Valuation
Enterprise Value
114.69M
P/E (Trailing)
‪-4.33‬
Price / Sales (TTM)
‪4.58‬
Price / Book
‪6.00‬
EV / EBITDA
‪-2.86‬
Profitability
Gross Margin
‪54.96%‬
Profit Margin
‪-102.33%‬
Operating Margin
‪-340.68%‬
Return on Assets
‪-11.66%‬
Return on Equity
‪-94.53%‬
Ownership
Shares Outstanding
100.69M
Float
46.78M
Held by Insiders
‪48.00%‬
Held by Institutions
‪10.42%‬
Price stats
Beta
‪2.75‬
50-Day Avg
‪2.54‬
200-Day Avg
‪3.21‬
Dividends
Payout Ratio
‪0.00%‬
Peers - ZVA - Cellectis S.A.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- ZVAFSXCellectis S.A.305.12MMarket Cap+21.78%52-week change-4.52P/E (Trailing)‪-102.33%‬Profit Margin
- ANLFSXAnalog Devices, Inc.155.74BMarket Cap+33.03%52-week change44.47P/E (Trailing)‪29.78%‬Profit Margin
- 1AEFSXargenx SE54.66BMarket Cap+32.95%52-week change39.15P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt54.41BMarket Cap+34.86%52-week change38.91P/E (Trailing)‪32.26%‬Profit Margin
- 0QFFSXModerna, Inc.50.02BMarket Cap+81.89%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 42ZFSXRevolution Medicines Inc.38.84BMarket Cap+82.79%52-week change-30.46P/E (Trailing)‪0.00%‬Profit Margin
- 49BAFSXBeOne Medicines, Ltd. American Depositary Receipt35.97BMarket Cap+14.46%52-week change66.67P/E (Trailing)‪10.69%‬Profit Margin
Profile Summary - ZVA - Cellectis S.A.
About
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf"…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
